SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2013.
For the fourth quarter of 2013, the Company reported a net loss of $10.6 million, or $0.16 loss per share, compared......
More...